A Case Challenge.

Slides:

Advertisements

Similar presentations

JOURNAL REVIEW Newer Antithrombotics in AF 1 Dr Ranjith MP Senior Resident Department of Cardiology Government Medical college Kozhikode.

Advertisements

ROCKET AF Renal Dysfunction Substudy Objective Evaluate the 2950 patients in the per-protocol cohort with a baseline CrCl of 30 to 49 mL/min who received.

ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.

Le basse dosi dei NAO: uso ed abuso Giuseppe Patti Campus Bio-Medico University of Rome.

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham.

A Challenging Case of Anticoagulant-Related GI Bleeding

Addressing the Challenges in Primary and Secondary Stroke Prevention

A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes

Anticoagulation in Atrial Fibrillation

Management of atrial fibrillation. Patterns of Atrial Fibrillation.

Covering the Bases in Cardioversion

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal Gregory.

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

Randomized Evaluation of Long-term anticoagulant therapY

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Novel oral anticoagulants in comparison with warfarin

Oral Anticoagulation and Preventing Stent Thrombosis

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Updates in Anticoagulation: What Did We Learn From ESC 2017?

US Guidelines US Guidelines Low-risk Patients.

When Is Adding Aspirin to NOACs Worth the Risk?

Thrombosis, Cancer, and NOACs

Access to NOAC Therapy:

Emergency Management of NOAC Bleeding

A New Era for NOACs:.

Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

The Safety and Efficacy of Full vs

POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF

Unmet Needs in the Secondary Prevention in ACS

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Up to Date on Which NOAC for Which Patient

Through Thick and Thin.

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

The Essentials for Secondary Stroke Prevention

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

NOACS: Emerging data in ACS/IHD

Efficacy and Safety of Edoxaban in Patients With AF and HF

AF and PCI in Practice.

Access to NOAC Therapy:

Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.

A Better Solution For Cancer Patients With VTE?

Reversal Strategies for VKA: Truths and Misconceptions

Oral Anticoagulation in AF

Dos and Don’ts for High-Risk Elderly Patients With AF

Practical Considerations to Extend Treatment for VTE

Atrial Fibrillation.

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Anticoagulation and Thrombosis Management

Aspirin and Cardioprevention in 2018

Identifying High-Risk AF Patients

CAD/PAD in Primary Care

A Time for Change for Managing Patients With VTE Who Have Cancer

What You Didn't Know About AF and Renal Dysfunction

Cancer-Associated Thrombosis

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Antithrombotic Therapy in Vascular Protection: From CAD to HF

Updates in Anticoagulation: Key Sessions at ESC 2017

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

5 Good Minutes on Atrial Fibrillation-related Stroke

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Gianluigi Savarese et al. JCHF 2016;4:

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

A Case Challenge

Case Patient Presentation

Antithrombotic Management in AF Patients With ACS/PCI

Oral Anticoagulation and AF Does Gender Matter?

Oral Anticoagulation and AF Does Gender Matter? (cont)

Efficacy and Safety Outcomes by Gender in RE-LY

Efficacy and Safety Outcomes by Gender in ROCKET AF

Efficacy and Safety Outcomes by Gender in ARISTOTLE

Age Distribution by Gender in ENGAGE AF - TIMI 48

Baseline Characteristics by Gender in ENGAGE AF – TIMI 48

Primary Efficacy and Safety in ENGAGE Outcomes by Gender

Annualized Rate of Major Bleed by Gender and Age (Warfarin) in ENGAGE

Secondary Safety Outcomes in ENGAGE Higher Dose Edox vs Warfarin

Secondary Safety Outcomes in ENGAGE Higher Dose Edox vs Warfarin (cont)